SCHEMBL770808

SCHEMBL770808

CC1CCCN(C(=O)CCNC(=O)N2CCCC3CCCCC32)C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
LMNA P02545 1/20 0.53
KMT2A Q03164 3/20 0.51
POLB P06746 2/20 0.50
MEN1 O00255 2/20 0.50
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 1/20 0.43
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
HSD11B1 P28845 1/20 0.41
GAA P10253 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770765 0.93 KMT2A (0.54) ALDH1A1LMNAKMT2APOLBMEN1
SCHEMBL770670 0.91 SMN1; SMN2 (0.41) ALDH1A1LMNAKMT2APOLBMEN1
SCHEMBL770958 0.88 ALDH1A1 (0.47) ALDH1A1LMNAKMT2APOLBMEN1
SCHEMBL771182 0.86 NPC1 (0.46) SMN1; SMN2RAB9ANPC1HSD11B1
SCHEMBL770864 0.86 NPC1 (0.46) SMN1; SMN2RAB9ANPC1HSD11B1
SCHEMBL770244 0.86 NPC1 (0.46) SMN1; SMN2RAB9ANPC1HSD11B1
SCHEMBL770921 0.85 NPC1 (0.46) ALDH1A1LMNAKMT2APOLBSMN1; SMN2
SCHEMBL769759 0.85 ALDH1A1 (0.57) ALDH1A1LMNAKMT2APOLBMEN1
SCHEMBL770587 0.84 KMT2A (0.42) ALDH1A1LMNAKMT2APOLBMEN1
SCHEMBL769965 0.83 NPC1 (0.50) POLBSMN1; SMN2RAB9ANPC1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885LMNA 3155/4885KMT2A 3868/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885LMNA 3116/4885KMT2A 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.